Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation

Molecular and Cellular Biology

Volumn 26, Issue 1, 2006, Pages 63-76

  Tzatsos, Alexandros ^a,b   Kandror, Konstantin V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADENYLATE KINASE; DEXAMETHASONE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; ISOBUTYLMETHYLXANTHINE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110ALPHA; PROTEIN P85; PROTEIN P85ALPHA; RAPAMYCIN; SERINE; SP 600128; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLUCOSE; INSULIN RECEPTOR SUBSTRATE 1 PROTEIN; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; LEUCINE; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROPEPTIDE; PHOSPHOPROTEIN; PROTEIN; PROTEIN KINASE; RAPTOR PROTEIN, HUMAN; RHEB PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; DRUG EFFECT; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; RAT;

ANIMALIA; MAMMALIA; RAPTORES;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN; LEUCINE; MICE; MONOMERIC GTP-BINDING PROTEINS; MUTATION; NEUROPEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SERINE; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 33644886769     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.26.1.63-76.2006     Document Type: Article

References (75)

1. Ali, S. M., and D. M. Sabatini. 2005. Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J. Biol. Chem. 280:19445-19448.
2. Bouzakri, K., M. Roques, P. Gual, S. Espinosa, F. Guebre-Egziabher, J. P. Riou, M. Laville, Y. Le Marchand-Brustel, J. F. Tanti, and H. Vidal. 2003. Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52:1319-1325.
3. Brunn, G. J., P. Fadden, T. A. Haystead, and J. C. Lawrence, Jr. 1997. The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. J. Biol. Chem. 272:32547-32550.
4. Brunn, G. J., C. C. Hudson, A. Sekulic, J. M. Williams, H. Hosoi, P. J. Houghton, J. C. Lawrence, Jr., and R. T. Abraham. 1997. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99-101.
5. Burnett, P. E., R. K. Barrow, N. A. Cohen, S. H. Snyder, and D. M. Sabatini. 1998. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 95:1432-1437.
6. Carling, D. 2004. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci. 29:18-24.
7. Carvalho, E., P. A. Jansson, M. Axelsen, J. W. Eriksson, X. Huang, L. Groop, C. Rondinone, L. Sjostrom, and U. Smith. 1999. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. FASEB J. 13:2173-2178.
8. Cheatham, L., M. Monfar, M. M. Chou, and J. Blenis. 1995. Structural and functional analysis of pp70S6k. Proc. Natl. Acad. Sci. USA 92:11696-11700.
9. Clark, S. F., J. C. Molero, and D. E. James. 2000. Release of insulin receptor substrate proteins from an intracellular complex coincides with the development of insulin resistance. J. Biol. Chem. 275:3819-3826.
10. Cline, G. W., K. F. Petersen, M. Krssak, J. Shen, R. S. Hundal, Z. Trajanoski, S. Inzucchi, A. Dresner, D. L. Rothman, and G. I. Shulman. 1999. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N. Engl. J. Med. 341:240-246.
11. Corradetti, M. N., K. Inoki, N. Bardeesy, R. A. DePinho, and K. L. Guan. 2004. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18:1533-1538.
12. Dennis, P. B., N. Pullen, S. C. Kozma, and G. Thomas. 1996. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol. Cell. Biol. 16:6242-6251.
13. Esposito, D. L., Y. Li, A. Cama, and M. J. Quon. 2001. Tyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells. Endocrinology 142:2833-2840.
14. Kara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177-189.
15. Harrington, L. S., G. M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. Barnett, N. R. Leslie, S. Cheng, P. R. Shepherd, I. Gout, C. P. Downes, and R. F. Lamb. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213-223.
16. Hartman, M. E., M. Villela-Bach, J. Chen, and G. G. Freund. 2001. Frap-dependent serine phosphorylation of IRS-1 inhibits IRS-1 tyrosine phosphorylation. Biochem. Biophys. Res. Commun. 280:776-781.
17. Hay, N., and N. Sonenberg. 2004. Upstream and downstream of mTOR. Genes Dev. 18:1926-1945.
18. Huang, C., R. Somwar, N. Patel, W. Niu, D. Torok, and A, Klip. 2002. Sustained exposure of L6 myotubes to high glucose and insulin decreases insulin-stimulated GLUT4 translocation but upregulates GLUT4 activity. Diabetes 51:2090-2098.
19. Ido, Y., D. Carling, and N. Ruderman. 2002. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 51:159-167.
20. Inoki, K., Y. Li, T. Xu, and K. L. Guan. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17:1829-1834.
21. Inoki, K., Y. Li, T. Zhu, J. Wu, and K. L. Guan. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:648-657.
22. Inoki, K., T. Zhu, and K. L. Guan. 2003. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590.
23. Inoue, G., B. Cheatham, R. Emkey, and C. R. Kahn. 1998. Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2. J. Biol. Chem. 273:11548-11555.
24. Isotani, S., K. Hara, C. Tokunaga, H. Inoue, J. Avruch, and K. Yonezawa. 1999. Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J. Biol. Chem. 274:34493-34498.
25. Jacinto, E., R. Loewith, A. Schmidt, S. Lin, M. A. Ruegg, A. Hall, and M. N. Hall. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6:1122-1128.
26. Jiang, G., Q. Dallas-Yang, S. Biswas, Z. Li, and B. B. Zhang. 2004. Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo. Biochem. J. 377:339-346.
27. Kim, D. H., D. D. Sarbassov, S. M. Ali, J. E. King, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163-175.
28. Kim, J. K., A. Zisman, J. J. Fillmore, O. D. Peroni, K. Kotani, P. Perret, H. Zong, J. Dong, C. R. Kahn, B. B. Kahn, and G. I. Shulman. 2001. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J. Clin. Investig. 108:153-160.
29. Li, J., K. DeFea, and R. A. Roth. 1999. Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. J. Biol. Chem. 274:9351-9356.
30. Li, Y., K. Inoki, and K. L. Guan. 2004. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol. Cell. Biol. 24:7965-7975.
31. Lillioja, S., D. M. Mott, B. V. Howard, P. H. Bennett, H. Yki-Jarvinen, D. Freymond, B. L. Nyomba, F. Zurlo, B. Swinburn, and C. Bogardus. 1988. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N. Engl. J. Med. 318:1217-1225.
32. Lizcano, J. M., O. Goransson, R. Toth, M. Deak, N. A. Morrice, J. Boudeau, S. A. Hawley, L. Udd, T. P. Makela, D. G. Hardie, and D. R. Alessi. 2004. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23:833-843.
33. Loewith, R., E. Jacinto, S. Wullschleger, A. Lorberg, J. L. Crespo, D. Bonenfant, W. Oppliger, P. Jenoe, and M. N. Hall. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10:457-468.
34. Long, X., Y. Lin, S. Ortiz-Vega, K. Yonezawa, and J. Avruch. 2005. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15:702-713.
35. Long, X., S. Ortiz-Vega, Y. Lin, and J. Avruch. 2005. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J. Biol. Chem. 280:23433-23436.
36. Moser, B. A., P. B. Dennis, N. Pullen, R. B. Pearson, N. A. Williamson, R. E. Wettenhall, S. C. Kozma, and G. Thomas. 1997. Dual requirement for a newly identified phosphorylation site in p70s6k. Mol. Cell. Biol. 17:5648-5655.
37. Musi, N., M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. Williamson, O. Ljunqvist, S. Efendic, D. E. Moller, A. Thorell, and L. J. Goodyear. 2002. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074-2081.
38. Myers, M. G., Jr., Y. Zhang, G. A. Aldaz, T. Grammer, E. M. Glasheen, L. Yenush, L. M. Wang, X. J. Sun, J. Blenis, J. H. Pierce, and M. F. White. 1996. YMXM motifs and signaling by an insulin receptor substrate 1 molecule without tyrosine phosphorylation sites. Mol. Cell. Biol. 16:4147-4155.
39. Nishiuma, T., K. Hara, Y. Tsujishita, K. Kaneko, K. Shii, and K. Yonezawa. 1998. Characterization of the phosphoproteins and protein kinase activity in mTOR immunoprecipitates. Biochem. Biophys. Res. Commun. 252:440-444.
40. Nojima, H., C. Tokunaga, S. Eguchi, N. Oshiro, S. Hidayat, K. Yoshino, K. Hara, N. Tanaka, J. Avruch, and K. Yonezawa. 2003. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278:15461-15464.
41. Oshiro, N., K. Yoshino, S. Hidayat, C. Tokunaga, K. Hara, S. Eguchi, J. Avruch, and K. Yonezawa. 2004. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9:359-366.
42. Ozes, O. N., H. Akca, L. D. Mayo, J. A. Gustin, T. Maehama, J. E. Dixon, and D. B. Donner. 2001. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc. Natl. Acad. Sci. USA 98:4640-4645.
43. Patti, M. E., E. Brambilla, L. Luzi, E. J. Landaker, and C. R. Kahn. 1998. Bidirectional modulation of insulin action by amino acids. J. Clin. Investig. 101:1519-1529.
44. Pirola, L., S. Bonnafous, A. M. Johnston, C. Chaussade, F. Portis, and E. Van Obberghen. 2003. Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signaling pathways in L6 muscle cells. J. Biol. Chem. 278:15641-15651.
45. Powers, A. C. 2001. Diabetes mellitus, p. 2109-2137. In E. Braunwald, S. A. Fauci, L. D. Karsper, L. S. Hauser, L. D. Longo, and J. L. Jameson (ed.), Harrison's principles of internal medicine, 15th ed. McGraw-Hill Book Co., New York, N.Y.
46. Pullen, N., P. B. Dennis, M. Andjelkovic, A. Dufner, S. C. Kozma, B. A. Hemmings, and G. Thomas. 1998. Phosphorylation and activation of p70s6k by PDK1. Science 279:707-710.
47. Richardson, C. J., M. Broenstrup, D. C. Fingar, K. Julich, B. A. Ballif, S. Gygi, and J. Blenis. 2004. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr. Biol. 14:1540-1549.
48. Rondinone, C. M., L. M. Wang, P. Lonnroth, C. Wesslau, J. H. Pierce, and U. Smith. 1997. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. USA 94:4171-4175.
49. Saitoh, M., N. Pullen, P. Brennan, D. Cantrell, P. B. Dennis, and G. Thomas. 2002. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J. Biol. Chem. 277:20104-20112.
50. Sakamoto, K., A. McCarthy, D. Smith, K. A. Green, D. Grahame Hardie, A. Ashworth, and D. R. Alessi. 2005. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 24:1810-1820.
51. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
52. Sarbassov, D. D., S. M. Ali, D. H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296-1302.
53. Saucedo, L. J., X. Gao, D. A. Chiarelli, L. Li, D. Pan, and B. A. Edgar. 2003. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol. 5:566-571.
54. Schalm, S. S., and J. Blenis. 2002. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12:632-639.
55. Schalm, S. S., D. C. Fingar, D. M. Sabatini, and J. Blenis. 2003. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13:797-806.
56. Scheele, J. S., J. M. Rhee, and G. R. Boss. 1995. Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. Proc. Natl. Acad. Sci. USA 92:1097-1100.
57. Shah, O. J., Z. Wang, and T. Hunter. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS 1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14:1650-1656.
58. Shaw, R. J., N. Bardeesy, B. D. Manning, L. Lopez, M. Kosmatka, R. A. DePinho, and L. C. Cantley. 2004. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99.
59. Shaw, R. J., M. Kosmatka, N. Bardeesy, R. L. Hurley, L. A. Witters, R. A. DePinho, and L. C. Cantley. 2004. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 101:3329-3335.
60. Shulman, G. I. 2000. Cellular mechanisms of insulin resistance. J. Clin. Investig. 106:171-176.
61. Shulman, G. I., D. L. Rothman, T. Jue, P. Stein, R. A. DeFronzo, and R. G. Shulman. 1990. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N. Engl. J. Med. 322:223-228.
62. Sommerfeld, M. R., S. Metzger, M. Stosik, N. Tennagels, and J. Eckel. 2004. In vitro phosphorylation of insulin receptor substrate 1 by protein kinase C-zeta: functional analysis and identification of novel phosphorylation sites. Biochemistry 43:5888-5901.
63. Stumvoll, M., N. Nurjhan, G. Perriello, G. Dailey, and J. E. Gerich. 1995. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333:550-554.
64. Sykiotis, G. P., and A. G. Papavassiliou. 2001. Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Mol. Endocrinol. 15:1864-1869.
65. Tremblay, F., A. Gagnon, A. Veilleux, A. Sorisky, and A. Marette. 2005. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 146:1328-1337.
66. Tremblay, F., and A. Marette. 2001. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J. Biol. Chem. 276:38052-38060.
67. Um, S. H., F. Frigerio, M. Watanabe, F. Picard, M. Joaquin, M. Sticker, S. Fumagalli, P. R. Allegrini, S. C. Kozma, J. Auwerx, and G. Thomas. 2004. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200-205.
68. Viollet, B., F. Andreelli, S. B. Jorgensen, C. Perrin, A. Geloen, D. Flamez, J. Mu, C. Lenzner, O. Baud, M. Bennoun, E. Gomas, G. Nicolas, J. F. Wojtaszewski, A. Kahn, D. Carting, F. C. Schuit, M. J. Birnbaum, E. A. Richter, R. Burcelin, and S. Vaulont. 2003. The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Investig. 111:91-98.
69. Weng, Q. P., K. Andrabi, A. Klippel, M. T. Kozlowski, L. T. Williams, and J. Avruch. 1995. Phosphatidylinositol 3-kinase signals activation of p70 S6 kinase in situ through site-specific p70 phosphorylation. Proc. Natl. Acad. Sci. USA 92:5744-5748.
70. Weng, Q. P., K. Andrabi, M. T. Kozlowski, J. R. Grove, and J. Avruch. 1995. Multiple independent inputs are required for activation of the p70 S6 kinase. Mol. Cell. Biol. 15:2333-2340.
71. Weng, Q. P., M. Kozlowski, C. Belham, A. Zhang, M. J. Comb, and J. Avruch. 1998. Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J. Biol. Chem. 273:16621-16629.
72. Werner, E. D., J. Lee, L. Hansen, M. Yuan, and S. E. Shoelson. 2004. Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J. Biol. Chem. 279:35298-35305.
73. Yaffe, M. B., K. Rittinger, S. Volinia, P. R. Caron, A. Aitken, H. Leffers, S. J. Gamblin, S. J. Smerdon, and L. C. Cantley. 1997. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91:961-971.
74. Yoo, L. I., D. C. Chung, and J. Yuan. 2002. LKB1-a master tumour suppressor of the small intestine and beyond. Nat. Rev. Cancer 2:529-535.
75. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear, and D. E. Moller. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Investig. 108:1167-1174.